Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | EPIK-P1 study: alpelisib for PIK3CA-related overgrowth spectrum disorders

Guillaume Canaud, MD, PhD, Université de Paris, Paris, France, gives an overview of PIK3CA-related overgrowth spectrum (PROS) and of the EPIK-P1 clinical trial (NCT04285723). PROS is a condition caused by PIK3CA gain-of-function mutations and associated with vascular anomalies. The EPIK-P1 study has evaluated the efficacy and safety of alpelisib, a PI3Kα inhibitor, for the first time in 57 patients. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.